3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street
The genomic revolution is upon us, but you wouldn't know it just by looking at the share prices of these three stocks. Shares of Fulgent Genetics (NASDAQ: FLGT), Amyris (NASDAQ: AMRS), and Pacific Biosciences of California (NASDAQ: PACB) have been absolutely hammered over the past several months.
Wall Street analysts who get paid to pay attention to these businesses think the stock market beatings they've received are totally unjustified. Here's why the price targets they set for these genomics stocks suggest gains of 60% or more just up ahead.
Image source: Getty Images.
Source Fool.com